Fabhalta
Payments companies reported to CMS as associated with Fabhalta. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Fabhalta, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Fabhalta
These are the largest totals companies reported as associated with Fabhalta. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Bhumika Patel | Greenville, SC | Hematology & Oncology | $26,147.86 |
| Kirk Campbell | New York, NY | Nephrology (Internal Medicine) | $25,036.19 |
| Caroline Piatek | Los Angeles, CA | Hematology (Internal Medicine) | $21,538.27 |
| Jessica Coleman | Beaufort, SC | Nephrology (Internal Medicine) | $20,993.58 |
| Sayna Norouzi | Loma Linda, CA | Nephrology (Internal Medicine) | $20,750.32 |
| Tingting Li | Saint Louis, MO | Nephrology (Internal Medicine) | $20,737.36 |
| Sanjiv Anand | South Salt Lake, UT | Nephrology (Internal Medicine) | $20,685.11 |
| Anjay Rastogi | Los Angeles, CA | Nephrology (Internal Medicine) | $20,674.49 |
| Joseph Habboushe | New York, NY | Emergency Medicine | $20,500.00 |
| Graham Walker | Stanford, CA | Emergency Medicine | $20,500.00 |
Prescribed Fabhalta?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.